ReviewCritical reviews in immunology2009
Immunotherapeutic approaches for glioma.
Review in Critical reviews in immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 157 citations in OpenAlex.
- Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Trial
- The evolution of chemotherapy in brain tumors: from historical milestones to precision medicine in glioblastoma.Exploration of targeted anti-tumor therapy · 2026Review
- Assessing brain metastasis response to immunotherapy: a pictorial review of atypical responses and intracranial adverse events.Insights into imaging · 2025Article
- Advances in Cellular Immune Theranostic Approaches for Glioblastoma: Current Trends and Future Directions.Cancer innovation · 2025Review
- Improving IL12 immunotherapy in glioblastoma by targeting the long noncoding RNA INCR1.Journal of neuro-oncology · 2025Article
- Unite and Conquer: Association of Two G-Quadruplex Aptamers Provides Antiproliferative and Antimigration Activity for Cells from High-Grade Glioma Patients.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Review
- Opportunities for improving brain cancer treatment outcomes through imaging-based mathematical modeling of the delivery of radiotherapy and immunotherapy.Advanced drug delivery reviews · 2022Review
- The current landscape of immunotherapy for pediatric brain tumors.Nature cancer · 2022Review
- Genetically Modified Cellular Therapies for Malignant Gliomas.International journal of molecular sciences · 2021Review
- Glioma progression is suppressed by Naringenin and APO2L combination therapy via the activation of apoptosis in vitro and in vivo.Investigational new drugs · 2020Article
- Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.Cancer biology & medicine · 2020Review
- Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.Cancer immunology, immunotherapy : CII · 2019Article
- Road map for fibrolamellar carcinoma: progress and goals of a diversified approach.Journal of hepatocellular carcinoma · 2019Article
- Conventional and advanced magnetic resonance imaging in patients with high-grade glioma.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... · 2018Review
- Article
- Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.The Journal of experimental medicine · 2018Article
- CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors.Frontiers in oncology · 2018Review
- Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.Frontiers in immunology · 2018Review
- Imaging in neuro-oncology.Therapeutic advances in neurological disorders · 2018Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
The development of effective immunotherapy strategies for glioma requires adequate understanding of the unique immunological microenvironment in the central nervous system (CNS) and CNS tumors. Although the CNS is often considered to be an immunologically privileged site and poses unique challenges for the delivery of effector cells and molecules, recent advances in technology and discoveries in CNS immunology suggest novel mechanisms that may significantly improve the efficacy of immunotherapy against gliomas. In this review, we first summarize recent advances in the CNS and CNS tumor immunology. We address factors that may promote immune escape of gliomas. We also review advances in passive and active immunotherapy strategies for glioma, with an emphasis on lessons learned from recent early-phase clinical trials. We also discuss novel immunotherapy strategies that have been recently tested in non-CNS tumors and show great potential for application to gliomas. Finally, we discuss how each of these promising strategies can be combined to achieve clinical benefit for patients with gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.